Pump.Science launch platform coming soon—can the new compound project match Rif/Uro?

Author: Biteye

First Pump.fun with its daily revenue of tens of millions of dollars, now Four.Meme endorsed by CZ—launchpad platforms onchain continue to exhibit strong casino-like effects. On February 8, the long-silent DeSci (Decentralized Science) sector also saw veteran project Pump.Science announce that its new launchpad will go live next week. Immediately after the news broke, $Rif and $Uro both rebounded by 20%. Previously,

Pump.Science co-founder Benjels stated in an interview that he planned to launch 20 new compound tokens by Christmas 2024.

In reality, however, he delayed this move until now. Over the past three months, affected by external factors such as interest rate cuts, Pump.Science's native tokens $Rif and $Uro dropped over 95% from their market cap peaks of 240m and 140m respectively. During the same period, BIO, a financial layer project in the DeSci space, fell around 90% from its peak after launching on Binance. The DeSci sector, once championed by influencers like CZ and Vitalik, now appears devastated. It seems this once-promising narrative meant to drive mass adoption has become widely discredited.

Will the Pump.Science new launchpad spark a DeSci revival?

According to official community documentation from Pump.Science, the new launchpad process is as follows:

① Users list a compound alongside a token on the Pump.Science platform.

② Users can buy and sell tokens on a Bonding Curve with parameters identical to Pump.fun to support research into the compound. 79% of the tokens are issued along the Bonding Curve. When the token market cap reaches 303 Sol (with 85 Sol in circulation), the Bonding Curve closes. 82 Sol of liquidity will migrate to Meteora for trading. 3 Sol will be used to cover associated worm experiment costs.

Notably, the Pump.Science new launchpad will implement a dynamic fee structure designed to deter sniper bots and prevent automated exploits during initial token sales. Specific measures include:

① Bot deterrence: The dynamic fee structure is specifically designed to reduce front-running by sniper bots.

② Early risk: Fees are extremely high (99.99%) during the first 150 slots (approximately 2 minutes), drastically reducing the number of tokens received by early buyers.

③ Activity monitoring: Between slots 150–250 (2–4 minutes), fees decrease rapidly.

Dynamic fee structure curve:

The whitepaper also states that all new compounds must airdrop a certain portion to builders and holders of $Rif and $Uro. Undoubtedly, Pump.Science’s launch of a new token platform is a large-scale act of “self-rescue.” The sluggish DeSci sector urgently needs fresh attention and a wealth-generation effect. Today, hunters on the Solana chain have grown exhausted chasing countless AI agents and celebrity tokens, while BSC sees CZ openly diverting attention. Amid such on-chain volatility, can another wave of DeSci enthusiasm akin to Rif and Uro emerge to break through? Can new compounds, new developers, and new attention influx revitalize more DeSci gameplay and bring in much-needed momentum? Three months after the initial fanfare around DeSci projects, the sector now stands at a critical juncture—determining whether DeSci will revive or fade into oblivion.

Overfunded presale returns 90%—new compound EGS draws buzz with "$Pain-style" fair launch

At 3:19 AM on February 9, Pump.Science's official Twitter commented on its upcoming compound project $EGS @EGCGxSFN, saying, "Earning trust is the most admirable thing." Scrolling through Twitter reveals that Pump.Science’s new compound project $EGS quietly opened a 24-hour presale window on February 7. On-chain data shows that $EGS’s presale wallet ultimately raised 1,223 Sol by block height 319172095. More strikingly, the team announced they would return 91.87% of the funds raised, retaining only 100 Sol for token launch and liquidity support. This "overfunded refund" strategy mirrors the popular $pain project, but EGS sets a precedent in both action and scale within the DeSci space. The EGS team declared on Twitter: "In 24 hours, no marketing, no whales—we proved trust in science." They further announced that EGS will reward DeSci’s diamond-handed supporters with a 100k market cap opening, and valid contributions during presale already yielded roughly triple profits.

EGS is the abbreviation for the compounds Epigallocatechin Gallate and Sulforaphane. EGCG, a core active ingredient in green tea, is hailed as the "king of antioxidants," known to inhibit cellular aging via AMPK pathway activation and reduce oxidative damage by scavenging free radicals. Studies show EGCG can extend the lifespan of model organisms like nematodes and fruit flies by up to 20%, through mechanisms including suppression of pro-inflammatory factors, enhanced mitochondrial function, and potential epigenetic regulation of telomere shortening. Sulforaphane, derived from cruciferous vegetables like broccoli, acts as a "cellular guardian" by significantly boosting antioxidant capacity via Nrf2 pathway activation. Experiments confirm Sulforaphane extends mouse lifespan by about 15%, primarily by promoting autophagy to clear senescent cells, repairing DNA damage, and suppressing age-related chronic inflammation (e.g., NF-κB pathway). Both compounds synergistically delay aging through multi-target mechanisms, making them rare natural candidates with clinical translation potential.

Clearly, the new compound inherits the IP monetization logic of Rif and Uro while lowering risk through high presale refunds—an ideal "low-barrier, high-upside" narrative DeSci desperately needs. Yet, whether such a media-savvy presale model, combined with DeSci’s “trust in science” narrative, can align with the success of Rif and Uro post-launch remains uncertain. Pump.Science co-founder Benjels frankly admitted, "The problem with DeSci is that the narrative is grand, but execution is hard. Users want to support science while also seeking speculative gains—the balance between the two is key." In today’s market where price pumps define legitimacy, the standalone decentralized science narrative has proven insufficient. The path to DeSci revival remains long and arduous, requiring more eye-catching mechanics to capture the crypto community’s fleeting attention. Let us hope this time, Pump.Science’s new compounds bring fresh momentum to the battered DeSci sector, and—as promised in their tweets—deliver both financial and emotional rewards to those steadfast DeSci diamond hands.

Appendix:

Pump.Science

New Compounds Overview

-Punicalagin & Berberine: Pomegranate polyphenols with strong antioxidant and anti-inflammatory properties; Berberine: an AMPK activator that regulates blood sugar and improves metabolic health. Together, pomegranate polyphenols support cardiovascular health and anti-inflammatory pathways, complementing berberine’s metabolic effects.

- Resveratrol & Berberine: Resveratrol, a polyphenol that activates sirtuins, enhances mitochondrial efficiency, and mimics calorie restriction; Berberine: an AMPK activator that regulates blood sugar and improves metabolic health. Together, both activate AMPK and sirtuins, potentially enhancing longevity, metabolic control, and cellular repair.

-Ginsenoside Rh2: A bioactive compound in ginseng with anticancer, neuroprotective, and anti-inflammatory effects.

-Aspalathin & Caffeine: Aspalathin, a bioactive flavonoid in rooibos tea with antioxidant and blood sugar-lowering effects; Caffeine: a stimulant that boosts mental and physical performance. Together, aspalathin may offset caffeine’s potential negative impacts on blood sugar and stress hormones, providing a more balanced stimulant response.

-Gossypol & Catechin Hydrate: Gossypol, a polyphenol with potential anticancer and metabolic benefits; Catechin hydrate, a catechin similar to EGCG with strong antioxidant properties. Together, these compounds may jointly regulate cellular stress responses and improve metabolic efficiency.

-Biotin & Berberine: Biotin, essential for fatty acid metabolism, glucose regulation, and skin health; Berberine: a metabolic regulator that improves insulin sensitivity. Together, biotin may enhance lipid metabolism and mitochondrial function, complementing berberine’s effects.

-Urolithin A & EGCG: Urolithin A, a metabolite derived from pomegranate that promotes mitophagy (recycling of damaged mitochondria); EGCG, a green tea catechin with strong antioxidant and anti-inflammatory properties. Together, both support mitochondrial function and longevity pathways, potentially improving cellular energy efficiency.

-Berberine & Quercetin: Berberine, a metabolic regulator that improves insulin sensitivity, lowers blood sugar, and supports cardiovascular health; Quercetin, a flavonoid with anti-inflammatory, antioxidant, and antiviral properties that enhances nutrient absorption. Together, quercetin increases berberine’s bioavailability and complements its metabolic effects, improving glucose regulation and mitochondrial function.

-Hesperidin & DHM (Dihydromyricetin): Hesperidin, a flavonoid found in citrus fruits that improves circulation, reduces oxidative stress, and supports vascular health; DHM (Dihydromyricetin), known for liver protection, alcohol metabolism support, and neuroprotection. Both regulate liver enzymes and inflammatory pathways, enhancing detoxification and metabolic recovery.

-EGCG: Green tea catechin with strong antioxidant and anti-inflammatory effects.

-Caffeine: Stimulant that enhances energy, cognitive function, and endurance. Supports liver detoxification and reduces premature mortality.

-Artemisinin: Extracted from sweet wormwood, with antimalarial, anticancer, and anti-inflammatory properties.

Recently, as Binance Research republished positive analysis on the DeSci sector, BIO, Rif, and Uro all surged 20%. It seems the wind for DeSci may be picking up again. Meanwhile, these compounds are about to launch on Pump.Science’s new platform. With such broad token distribution, it’s crucial to keep an eye on high-quality tokens and identify projects that are both serious and creatively engaging. DYOR!